PIK3CD and activated PI3K-delta syndrome: On the other hand, leniolisib (CDZ173), a potent and selective oral inhibitor of PI3Kdelta (128), has been successfully used in a series of patients with APDS, in which PI3Kdelta gain-of-function mutation results in lymphoproliferation of the MALT, T-cell senescence and immunodeficiency.